Search - tctmd.com

Displaying 1 - 20 of 128

Sort: Relevancy | Date

Presentation EuroPCR 2025

Final seven-year outcome of the COMPARE-ABSORB trial

Presenter: Pieter Smits

May 22, 2025

Presentation TCT 2024

TCT 915: Predictors of Conduction System Disturbances Resulting in a New Permanent Pacemaker Implantation Within the LANDMARK Trial

Presenter: Pieter Smits

October 30, 2024

Presentation TCT 2024

Future Metallic Drug Eluting Stents: New Designs, Platforms, and Components

Presenter: Pieter Smits

October 30, 2024

Presentation TCT 2024

TCT 130: Conduction Disturbances and Permanent Pacemaker Implantation After Myval Transcatheter Heart Valve or Contemporary Standard Valves (Sapien and Evolut) Implantation: LANDMARK Trial

Presenter: Pieter Smits

October 29, 2024

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

Presentation TCT 2023

Beyond LDL

Presenter: Pieter Smits

October 26, 2023

Presentation TCT 2023

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Presenter: Pieter Smits

October 25, 2023

Presentation TCT 2022

Does It Matter What Stent I Use in a HBR Patient?

Presenter: Pieter Smits

September 18, 2022

News Conference News EuroPCR 2022

Robotic PCI Safe, Feasible in Noncomplex Cases: R-Evolution

Yael L. Maxwell

May 18, 2022

Podcast TCTMD Talking Points

MASTER DAPT: High-Risk Patients

April 20, 2022

Presentation TCT 2021

Case-Based Learning: Managing Non-culprit Lesions in the STEMI Patient With Coronary Physiology

Presenter: Pieter Smits

November 06, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

Presentation TCT 2021

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

Presenter: Pieter Smits

November 05, 2021

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

Shelley Wood

September 02, 2021

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Shelley Wood

August 28, 2021

News Daily News CRT 2021

COMPARE-ABSORB: 3-Year Results Hint at Stabilization With Bioresorbable Scaffold

Michael O'Riordan

March 17, 2021

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

News Daily News

Functionally Significant Nonculprit Lesions Pose Risk in STEMI Patients

Michael O'Riordan

April 21, 2020

Presentation TCT 2019

Not So Fast: There Is So Much More to Learn!

Presenter: Pieter Smits

September 26, 2019

Podcast TCTMD Talking Points

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

July 17, 2019

Advertisement

Final seven-year outcome of the COMPARE-ABSORB trial

TCT 915: Predictors of Conduction System Disturbances Resulting in a New Permanent Pacemaker Implantation Within the LANDMARK Trial

Future Metallic Drug Eluting Stents: New Designs, Platforms, and Components

TCT 130: Conduction Disturbances and Permanent Pacemaker Implantation After Myval Transcatheter Heart Valve or Contemporary Standard Valves (Sapien and Evolut) Implantation: LANDMARK Trial

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Beyond LDL

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Does It Matter What Stent I Use in a HBR Patient?

Robotic PCI Safe, Feasible in Noncomplex Cases: R-Evolution

MASTER DAPT: High-Risk Patients

Case-Based Learning: Managing Non-culprit Lesions in the STEMI Patient With Coronary Physiology

More DAPT Duration Data, More Calls to Tailor to Individual Patients

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

COMPARE-ABSORB: 3-Year Results Hint at Stabilization With Bioresorbable Scaffold

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

Functionally Significant Nonculprit Lesions Pose Risk in STEMI Patients

Not So Fast: There Is So Much More to Learn!

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content